rs5743708 — TLR2 R753Q

TLR2 R753Q — A Crack in the Innate Immune Front Line

Every time your body encounters a bacterium, a first-responder system fires before the adaptive immune response even wakes up. Toll-Like Receptor 2 (TLR2)¹¹ Toll-Like Receptor 2 (TLR2)
TLR2 is a pattern-recognition receptor on the surface of macrophages, monocytes, dendritic cells, and epithelial cells stands at this front line, recognizing bacterial lipoproteins, peptidoglycan, lipoteichoic acid, and mycobacterial components. The R753Q variant (rs5743708), caused by a G-to-A transition at nucleotide 2258, replaces the positively charged arginine with neutral glutamine at position 753 in the receptor's TIR domain²² TIR domain
the Toll/IL-1 receptor domain — the intracellular signaling region that recruits adaptor proteins and initiates the inflammatory cascade. This single amino acid swap disables much of TLR2's capacity to fire.

The R753Q variant is almost exclusively a European polymorphism: approximately 3% of people of European descent carry at least one copy, compared to less than 0.3% in African and East Asian populations. This population specificity makes it a particularly important variant for European-ancestry users.

The Mechanism

The substitution of glutamine for arginine at position 753 changes the electrostatic potential of the DD loop³³ electrostatic potential of the DD loop
a structural element in the TIR domain critical for protein-protein interactions — the precise region where adaptor proteins dock onto TLR2. The consequences cascade through the entire signaling chain: R753Q TLR2 exhibits severely impaired tyrosine phosphorylation⁴⁴ severely impaired tyrosine phosphorylation
4.8-7.5-fold reduction compared to wild-type — a proximal step required for signaling complex assembly, fails to efficiently dimerize with its partner TLR6 (5.9-8-fold reduction), and blocks recruitment of the adaptor proteins MAL and MyD88 that relay the signal to NF-κB.

The end result: where wild-type TLR2 produces 42-fold induction of IL-8 in response to inactivated Mycobacterium tuberculosis components, R753Q TLR2 produces only 4-fold induction⁵⁵ 4-fold induction
even a 100-fold increase in mutant TLR2 expression cannot overcome this deficit. The defect is qualitative, not merely quantitative — the receptor is functionally crippled regardless of how much of it is present. Studies using knock-in mice confirmed that macrophages expressing R753Q show reduced TNF-α, IL-1β, IL-6, and IL-10 production⁶⁶ reduced TNF-α, IL-1β, IL-6, and IL-10 production
along with impaired IRAK-1, p38, ERK1/2, and NF-κB p65 phosphorylation upon mycobacterial challenge.

The Evidence

Tuberculosis is the most extensively studied consequence. A meta-analysis of 19 case-control studies⁷⁷ meta-analysis of 19 case-control studies
4,970 tuberculosis cases and 4,105 controls from Asian and Caucasian populations found that the A allele confers an odds ratio of 2.80 for tuberculosis disease across all genetic models, rising to 5.80 for AA homozygotes. The risk is consistent across both Asian and Caucasian populations, though slightly higher in Asians (OR 3.42 vs 2.39 in Caucasians in the allelic model).

CMV after transplantation shows the most dramatic individual finding. A study of 737 liver transplant recipients⁸⁸ 737 liver transplant recipients
92 patients (12.5%) developed CMV disease within 24 months found that homozygosity for R753Q was associated with a hazard ratio of 3.41 for tissue-invasive CMV disease. This reflects TLR2's documented role in recognizing CMV glycoprotein B — cells expressing R753Q TLR2 show abrogated NF-κB activity when challenged with CMV⁹⁹ abrogated NF-κB activity when challenged with CMV
validating the clinical transplant findings with functional data.

Atopic dermatitis with a severe phenotype clusters in R753Q carriers. The polymorphism defines a distinct subgroup¹⁰¹⁰ defines a distinct subgroup
9 of 78 AD patients (11.5%) were heterozygous for R753Q with median SCORAD scores of 55.8 vs 44.8 in non-carriers, and all carriers had SCORAD above 30 — indicating at least moderate disease. All carriers showed higher total IgE and Dermatophagoides pteronyssinus-specific IgE. A subsequent meta-analysis of nine studies¹¹¹¹ meta-analysis of nine studies
OR 2.07 for atopic dermatitis risk in Caucasians with GA genotype confirmed this association. The mechanism links to impaired IL-8 secretion in response to S. aureus¹²¹² impaired IL-8 secretion in response to S. aureus
which colonizes the skin of nearly all severe AD patients and perpetuates the inflammatory cycle.

Sepsis susceptibility is also elevated. A study using both computational structural modeling and patient data found significant association between TLR2 Arg753Gln and sepsis¹³¹³ significant association between TLR2 Arg753Gln and sepsis
under the over-dominant model, p=0.043, consistent with the expected biology of reduced inflammatory signaling impairing bacterial clearance.

Practical Implications

The picture painted across all these studies is consistent: R753Q carriers mount a blunted initial response when TLR2 ligands are present. This matters most for gram-positive bacteria (which produce the peptidoglycan and lipoproteins TLR2 recognizes), mycobacteria, and certain viruses like CMV. The implications are practical: faster medical attention for infections, optimizing vaccination status, and — for those with atopic dermatitis — recognizing that S. aureus colonization management is especially important.

Lyme disease is a notable exception. Patients with R753Q show significantly lower frequency in severe late-stage Lyme disease¹⁴¹⁴ significantly lower frequency in severe late-stage Lyme disease
possibly due to reduced inflammatory pathology from attenuated TLR2 responses to Borrelia spirochetes, suggesting the dampened immune response can be protective when the disease is primarily driven by immune overactivation rather than pathogen burden.

Interactions

TLR2 does not act alone. It forms heterodimers with TLR1 (recognizing triacylated lipopeptides) and TLR6 (recognizing diacylated lipopeptides and lipoteichoic acid) — and R753Q directly impairs this dimerization. TLR1 rs5743618, a common coding variant, alters TLR1 surface expression and affects combined TLR1/TLR2 signaling; the CGG haplotype (rs5743618–rs5743708–rs5743810 in TLR6) was associated with increased leprosy susceptibility in a Colombian population, suggesting additive effects across the TLR1/2/6 recognition complex.

The CD14 gene (rs2569190)¹⁵¹⁵ CD14 gene (rs2569190)
CD14 encodes the co-receptor that presents bacterial lipopolysaccharide and lipoproteins to TLR2 and TLR4 encodes a co-receptor that delivers bacterial products to TLR2 and TLR4. CD14 variants that reduce its expression would compound TLR2 R753Q impairment, potentially amplifying the signaling deficit further.

For individuals with TLR2 R753Q who also carry TLR4 Asp299Gly (rs4986790), the innate immune system faces a double impairment: blunted gram-positive and mycobacterial recognition (TLR2) alongside reduced gram-negative endotoxin recognition (TLR4). This combined state would warrant heightened infection awareness across a wider pathogen spectrum.